Expanded Access trial of Paclitaxel (LSAM-PTX) for Chemoablation of Intraductal Papillary Mucinous Neoplasms
Latest Information Update: 14 Jun 2023
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
Most Recent Events
- 14 Jun 2023 New trial record
- 07 Jun 2023 Results presented in the NanOlogy Media Release.
- 01 May 2023 According to a NanOlogy media release, results from this trial were presented at the DDW 2023 in May.